University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Theranostics Symposium

December 18, 2019, 9:00 am – 12:00 pm

Mission Bay
550 16th Street
MH-1401/2
San Francisco, CA 94158

This symposium will feature presentations on various research being performed at UCSF that can have impact on radioligand therapy from radiochemistry, dosimetry, genomics, and benefits of combined therapy. Please note that this is an internal meeting for the UCSF community. Register for the symposium.

 

Meeting Agenda

Introduction

  • 9:00 am - Thomas Hope: “Introduction to Theranostics and Radioligand Therapy”
  • 9:10 am - Eric Small: “Pathways for Developing Cancer Center Programs”

Dosimetry and bone marrow toxicity

  • 9:20 am - Emily Bergsland: “PRRT for neuroendocrine tumors: Weighing the pros and cons in the setting of a rare but clinically important toxicity”
  • 9:30 am - Sara St. James: “All in a Gy: Reporting received radiation dose from theranostic agents”
  • 9:40 am - Youngho Seo: “Theranostics of MIBG in neuroblastoma”

Combination therapy related

  • 9:50 am - Rahul Aggarwal: “Immunogenic Priming with 177Lu-PSMA-617 in Chemotherapy-Naive Metastatic Castration Resistant Prostate Cancer”
  • 10:00 am - David Oh: “Imaging Immune Response with Granzyme Targeted Probes”
  • 10:10 am - Mary Helen Barcellos-Hoff: “TGFβ inhibitors in the context of DNA damage”
  • 10:20 am - Thomas OLoughlin: “"Identifying druggable modifiers of PSMA expression using CRISPRi”

Break at 10:30 am

Resources for theranostics research

  • 10:45 am - Henry VanBrocklin: “Radioisotopes to Radiopharmaceuticals: Preparation of Theranostic Agents”
  • 10:50 am - Ashley Mishoe: “UCSF Radiopharmaceutical Facility: clinical translation of theranostics”
  • 10:55 am - Veronica Steri / Byron Hann: “Preclinical Therpeutics Core (PTC) as a resource for Theranostics”

New agent development 

  • 11:00 am - Ka-Ngo Leung: “A New Compact Neutron Generator for Medical Isotope Production”
  • 11:10 am - Robert Flavell: “Targeting CD46 with novel theranostic agents for imaging and treatment of castration resistant prostate cancer”
  • 11:20 am - Charly Craik: “Targeting the plasminogen activation system for visualizing and treating aggressive cancers.”
  • 11:30 am - Mike Evans: “Leveraging cell surface proteomics data to develop new cancer theranostics”
  • 11:40 am - Henry VanBrocklin: “Targeting PSMA using phosphoramidate agents for imaging and therapy”

Discussion at 11:50 am
 

Faculty organizer: Thomas Hope, MD

 


Contact Information

Contact
meredith.donnelly@ucsf.edu

See more events